(54) Title: DELIVERY OF TIGECYCLINE IN THE PRESENCE OF HEPARIN

(57) Abstract: The present disclosure is directed to combination therapies of tigecycline and heparin and methods of administration of tigecycline and heparin.

Published: — without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guideance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
DELIVERY OF TIGECYCLINE IN THE PRESENCE OF HEPARIN

CO-ADMINISTRATION OF TIGECYCLINE AND HEPARIN

In one embodiment, the present disclosure is directed to combination therapies of tigecycline and heparin and methods of administration of tigecycline and heparin.

Tigecycline, (9-(t-butyl-glycylamido)-minocycline, TBA-MINO, (4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide, is a glycyclcline antibiotic and an analog of the semisynthetic tetracycline, minocycline. Tigecycline is a 9-t-butylglycylamido derivative of minocycline, formula (I):

```
     H3C  N\ CH3       H3C  N\ CH3
      O\ O\           O\ O\  NH2
       \ /            /\ /
     H3C\ C\ \ H3C     H3C\ C\ \ H3C
          /\            /\           \
        H3C\ C\ \ H3C     H3C\ C\ \ H3C
```

(TI)

Tigecycline, developed in response to the worldwide threat of emerging resistance to antibiotics, has expanded broad-spectrum antibacterial activity both in vitro and in vivo. Glycyclcline antibiotics, like tetracycline antibiotics, act by inhibiting protein translation in bacteria.


Tigecycline may be used in the treatment of many bacterial infections, such as complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), Community Acquired Pneumonia (CAP), and Hospital Acquired Pneumonia (HAP) indications, which may be caused by gram-negative and gram-positive pathogens, anaerobes, and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA). Additionally, tigecycline may be used to treat or control bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants. Also, tigecycline may be used to treat bone and joint infections, catheter-related bacteremia, Neutropenia, obstetrics and gynecological infections, or to treat other resistant pathogens, such as VRE, ESBL, enterics, rapid growing mycobacteria, and the like.

Hlavaka, et al., U.S. Patent No. 5,529,990 discloses a method of treating or controlling bacterial infections in warm-blooded animals comprising administering a pharmacologically effective amount of a 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline, of which tigecycline is a member of the genus described. U.S. Patent No. 5,529,990 also discloses a method of treating or controlling bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants comprising administering a pharmacologically effective amount of a 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline, of which tigecycline is a member of the genus described. U.S. Patent No. 5,529,990 is incorporated herein by reference in its entirety.

Tigecycline may be manufactured by lyophilization and formulated, for example, compounded in the hospital pharmacy, for reconstitution as an IV solution. Tigecycline will frequently be administered simultaneously with other diluents and drugs. Since the tigecycline and the other diluents or drugs are often contained in separate infusion "bags", the Y-sites on the administration set allow for the two solutions to be mixed together prior to using a common intravenous access point on the patient. Thus, in one
embodiment, the tigecycline should be compatible with the other diluents or drugs when the two solutions are mixed together.

Heparin ("heparin"), an anticoagulant, is a heterogeneous group of straight-chain anionic mucopolysaccharides, called, glycosaminoglycans having anticoagulant properties. Injectable heparin sodium, for example, is indicated for anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; in a low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease; prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and heart surgery; prophylaxis and treatment of peripheral arterial embolism; and as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes.

The tetracycline class (e.g., tetracycline, chlortetracycline, demeclocycline, minocycline, oxytetracycline, methacycline, and doxycycline) is a widely used antibiotic class. Some antibiotics in this class are known to be incompatible with the administration of heparin. Misgen, R., American Journal of Hospital Pharmacy (1965), 22(2), 92-4; Monnier, H. et al. ASHP Midyear Clinical Meeting, (Dec 1990) Vol. 25, p. P-186E. This incompatibility results in drawbacks in the administration of tetracyclines and heparin, such as, administration at the same site of a patient.

For example, minocycline, of which tigecycline is an analog, has a demonstrated incompatibility with heparin. See Minocin Prescribing Information, p. 14, http://www.wyeth.com/content/ShowLabeling.asp?id=118, revised May 5, 2005, (stating that "Minocin IV should not be mixed before or during administration with any solutions containing...heparin sodium...")

The incompatibility between heparin and some previously known tetracyclines and tetracycline derivatives is often manifested as a visual incompatibility indicated by precipitation of solids. For example, when some tetracyclines and heparin chloride are administered on the same administration set, a precipitation is observed. This
incompatibility usually requires a saline or other flush of the equipment prior to or after a heparin dose or requires a separate site of administration to the patient.

It has surprisingly been found here, however, that tigecycline may be administered with heparin. For example, tigecycline and heparin may be administered through a single administration site, such as through a Y-site mixing site, without a saline flush. In one embodiment, tigecycline and heparin do not have at least one of the incompatibilities of tetracyclines or tetracycline derivatives and heparin.

Disclosed is a composition comprising at least one glycyclcycline, such as tigecycline and heparin. Another embodiment is a combination therapy comprising administration of at least one glycyclcycline and heparin. A further embodiment is the coadministration of at least one glycyclcycline and heparin. Another embodiment is a pharmaceutical composition comprising at least one glycyclcycline and heparin and at least one pharmaceutically acceptable excipient. In one embodiment, tigecycline, as used herein, may be replaced or combined with other glycyclcyclines. Also disclosed are methods of using at least one glycyclcycline and heparin.

Another embodiment of the disclosure is a medical apparatus comprising at least two separate compartments, wherein a first compartment comprises at least one glycyclcycline and a second compartment comprises heparin, and wherein the first and second compartments are connected by a line. For example, the first and second compartments may be connected to the same administration set and the contents of the first and second compartments may be mixed prior to administration. By further example, the administration set may contain a Y-site where the contents of the first and second compartments are mixed prior to administration.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG 1 illustrates a common, clinical situation, where the admixed tigecycline is in the "Secondary" IV compartment, and the other diluents or drugs are in the "Primary" IV compartment.

Definitions

Throughout the specification and claims, including the detailed description below, the following definitions apply.
It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing "a compound" includes a mixture of two or more compounds. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.

"Glycylcycline" as used herein refers to any glycylox derivative of any tetracycline and includes any salt forms, such as any pharmaceutically acceptable salt, enantiomers and stereoisomers. See Sum P.E. et al. J Med Chem 1993;37:184–188. Glycylcycline, as used herein, may be formulated according to methods known in the art.

"Tigecycline" as used herein includes tigecycline in free base form and salt forms, such as any pharmaceutically acceptable salt, enantiomers and stereoisomers. Tigecycline, as used herein, may be formulated according to methods known in the art. By way of non-limiting example, tigecycline may be optionally combined with one or more pharmaceutically acceptable excipients, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight. Other formulations are discussed in U.S. Patent Nos. 5,494,903 and 5,529,990, which are herein incorporated by reference.

"Heparin" as used herein includes heparin and its derivatives, including low and ultra-low molecular weight heparins and pharmaceutically acceptable salts, such as chlorine and sodium salts. Heparin may also be formulated according to methods known in the art.

"Pharmaceutical composition" as used herein refers to a medicinal composition.

"Pharmaceutically acceptable excipient" as used herein refers to pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein.
including any such carriers known to those skilled in the art to be suitable for the particular mode of administration. For example, solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include a sterile diluent (e.g., water for injection, saline solution, fixed oil, and the like); a naturally occurring vegetable oil (e.g., sesame oil, coconut oil, peanut oil, cottonseed oil, and the like); a synthetic fatty vehicle (e.g., ethyl oleate, polyethylene glycol, glycerine, propylene glycol, and the like, including other synthetic solvents); antimicrobial agents (e.g., benzyl alcohol, methyl parabens, and the like); antioxidants (e.g., ascorbic acid, sodium bisulfite, and the like); chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA) and the like); buffers (e.g., acetates, citrates, phosphates, and the like); and/or agents for the adjustment of tonicity (e.g., sodium chloride, dextrose, and the like); or mixtures thereof. By further example, where administered intravenously, suitable carriers include physiological saline, phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol, polypropylene glycol, and the like, and mixtures thereof.

"Administration set" as used herein refers to a device used to administer fluids from a compartment to a patient's vascular system through a needle or catheter inserted into a vein. The device may include a needle or catheter, port(s) for administration set, roller clamps, slide clamps, "primary" and "secondary" IV fluid compartments or containers, Y-injection sites, adapters, sample collection container or venous access site on a patient, tubing, flow regulators, drip chambers, in-line filters, IV set stopcocks, fluid delivery tubing, infusion pump, connectors between parts of the set, side tube with a cap to serve as an injection site, hollow spikes to penetrate and connect the tubing to IV bags or other infusion fluid compartments.

"Y-site" as used herein refers to a mixing site of an administration set. A non-limiting example is shown in FIG 1.

"Incompatibility" as used herein refers to unsuitability for use of two drugs or diluents together because of chemical or other physical interaction.

"Co-administration" as used herein refers to administration of drug A at the same time as drug B, prior to or following the administration of drug B. In one embodiment,
the administration is immediately prior or following. In an embodiment of the invention drug A is tigecycline and drug B is heparin sodium.

“Combination therapy” as used herein refers to a therapy that utilizes co-administration of drug A and drug B. In an embodiment of the invention drug A is tigecycline and drug B is heparin sodium.

“Administration” as used herein refers to providing a composition orally, parenterally (via intravenous injection (IV), intramuscular injection (IM), depo-IM, subcutaneous injection (SC or SQ), or depo-SQ), sublingually, intranasally (inhalation), intrathecally, topically, or rectally.

“Therapeutically effective amount” as used herein refers to an amount of a therapeutic agent administered to a host to treat or prevent a condition treatable by administration of a composition described in the invention. The amount is the amount sufficient to reduce or lessen at least one symptom of the disease being treated or to reduce or delay onset of one or more clinical markers or symptoms of the disease.

The terms “pharmaceutically acceptable salt” and “salts thereof” refer to acid addition salts or base addition salts of the compounds in the present disclosure. A pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered. Pharmaceutically acceptable salts include salts of both inorganic and organic acids. Pharmaceutically acceptable salts include acid salts such as acetic, aspartic, axetil, benzenesulfonic, benzoic, boric, camphoric, citric, bitartraric, butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, clexetil, citric, edetic, edisyllic, estolic, esyl, esyllic, formic, fumaric, gluceptic, gluonic, glutamic, glycolylarsanilic, hexamic, hexylresorcinolic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, malic, maleic, malonic, mandelic, methanesulfonic, methylnitric, methylsulfuric, mucic, muconic, napsylic, nitric, oxalic, p-nitromethanesulfonic, pamoic, pantothenic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalactouronic, propionic, salicylic, stearic, succinic, sulfamic, sulfanilic, sulfonic, sulfuric, tannic, tartaric, teoclic, toluenesulfonic, and the like. Other acceptable salts may
be found, for example, in Stahl et al., Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH; 1st edition (June 15, 2002).

"Unit dosage form" used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect.

"Article of manufacture," "medical apparatus," and "medical product" as used herein refers to materials useful for prevention or treatment using, for example, tigecycline and heparin, such as a compartment with a label. The label can be associated with the article of manufacture in a variety of ways including, for example, the label may be on the compartment or the label may be in the compartment as a package insert. Suitable compartments include, for example, blister packs, bottles, bags, vials, syringes, test tubes, and the like. The compartments may be formed from a variety of materials such as glass, metal, plastic, rubber, paper, and the like. The article of manufacture may contain bulk quantities or less of tigecycline. The label on, or associated with, the compartment may provide instructions for the use of tigecycline, instructions for the dosage amount and for the methods of administration including compatibility with heparin. The article of manufacture may further comprise multiple compartments, also referred to herein as a kit. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and/or package inserts with instructions for use.

"SWFI" is sterile water for injection.

"NS" is normal saline.

Detailed Description of the Invention

Tigecycline is an antibiotic that may be used in the treatment of many bacterial infections, such as complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), Community Acquired Pneumonia (CAP), and Hospital Acquired Pneumonia (HAP) indications, which may be caused by gram-negative and gram-positive pathogens, anaerobes, and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA). Additionally, tigecycline may be used to treat or control bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants. Also, tigecycline may be used
to treat bone and joint infections, catheter-related bacteremia, Neutropenia, obstetrics and gynecological infections, or to treat other resistant pathogens, such as VRE, ESBL, enterics, rapid growing mycobacteria, and the like.

Other glycylcycline antibiotics may be used in place of tigecycline or in combination with tigecycline in the practice of the disclosure. Examples of other glycylcyclines include (9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline), (9-(N,N-dimethylglycylamido)-minocycline), and compounds included in U.S. Patent No. 5,494,903, which is herein incorporated by reference.

In addition to tigecycline, patients may be receiving other diluents or drugs at the same site of administration. FIG. 1 illustrates a common, clinical situation, where the admixed tigecycline would be in the "Secondary" IV compartment, and the other diluents or drugs are in the "Primary" IV compartment. Mixing of the two fluids occurs at the Y-site, and the period that the two fluids are together is related to a number of variables (e.g. flow rates of each fluid, location of Y-site, and fluid volume in administration set from the Y-site to the venous access site).

In one embodiment, since there may be a common point of administration and thus mixing of tigecycline and one or more diluent or drug, the diluent or drug should be compatible with tigecycline.

It has been discovered that tigecycline is compatible with the administration of heparin, and, for example, can be administered to a patient at a common point of administration. In one embodiment, tigecycline and heparin may be administered through a single common point administration site, such as through a Y-site mixing point, without a saline flush. In one embodiment, tigecycline and heparin do not have at least one of the incompatibilities of tetracyclines or tetracycline derivates with heparin.

Disclosed is a composition comprising at least one glycylcycline chosen from a compound of the formula
and pharmaceutically acceptable salts thereof, wherein:

X is selected from amino, NR^1R^2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R^1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R^2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR^1R^2 and R^1 =hydrogen,

R^2 =methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R^1 =methyl or ethyl,

R^2 =methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R^1 =n-propyl,

R^2 =n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R^1 =1-methylethyl,

R^2 =n-butyl, 1-methylpropyl or 2-methylpropyl; and when R^1 =n-butyl,

R^2 =n-butyl, 1-methylpropyl or 2-methylpropyl; and when R^1 =1-methylpropyl,

R^2 =2-methylpropyl;
R is selected from R^4 (CH_2)_n CO-- or R^4'' (CH_2)_n SO2--; and n=0-4;
and when R=R^4 (CH_2)_h CO- and n-0,
R^4 is selected from amino; monosubstituted amino selected from straight or branched
(C_1 - C_9)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or
phenylamino; disubstituted amino selected from dimethylamino, diethylamino,
ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl,
1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C_5-
C_9)cycloalkyl group with substitution selected from cyano, amino or (C_1-C_3)acyl; a
substituted (C_6-C_10)aryl group with substitution selected from halo, (C_1-C_4)alkoxy,
trihalo (C_1-C_3)-alkyl, nitro, amino, cyano, (C_1-C_4)alkoxycarbonyl (C_1-C_3)alkylamino
or carboxy; . -amino-(C_1-C_4)alkyl selected from aminomethyl, . -aminoethyl,
. -aminopropyl or . -amino-butyl; carboxy (C_2-C_4)-alkylamino selected from
aminoacetic acid, . -aminobutyric acid or. -aminopropionic acid and the optical
isomers thereof; (C_7-C_9)aralkylamino; (C_1-C_4)alkoxycarbonylamino substituted
(C_1-C_4) alkyl group;
15. -hydroxy(C_1-C_3)alkyl selected from hydroxymethyl, . -hydroxyethyl or
. -hydroxy-1-methylethyl or -hydroxypropyl; -mercapto (C_1-C_3)alkyl selected from
mercaptomethyl, . -mercaptoethyl, . -mercapto-1-methylethyl or, -mercaptopropyl;
halo-(C_1-C_2)alkyl group; a heterocycle selected from the group consisting of a
five membered aromatic or saturated ring with one N, O, S or Se heteroatom
optionally having a benzo or pyrido ring fused thereto, a five membered aromatic
ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring
fused thereto, a six membered aromatic ring with one to three N, O, S or Se
heteroatoms, or a six membered saturated ring with one or two N, O, S or Se
heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group
selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C_5-
C_9)cycloalkylcarbonyl, (C_6-C_10)aryl selected from benzoyl or naphthoyl; halo
substituted (C_6-C_10)aryl; (C_1-C_4) alkylbenzoyl, or (heterocycle)-carbonyl, the
heterocycle as defined hereinabove;
(C_1-C_4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or
branched propoxycarbonyl, straight or branched butoxycarbonyl or
allyloxy carbonyl; a substituted vinyl group with substitution selected from
halogen, halo(C₁-C₃)alkyl, or a substituted (C₆-C₁₀)aryl group with substitution
selected from halo, (C₁-C₄)-alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-
C₄)alkoxycarbonyl, (C₁-C₃)alkylamino or carboxy;
(C₁-C₄)alkoxy group; C₆-aryloxy selected from phenoxy or substituted phenoxy with
substitution selected from halo, (C₁-C₄) alkyl, nitro, cyano, thiol, amino, carboxy,
di(C₁-C₃)alkylamino; (C₇-C₁₀)aralkyloxy; vinyloxy or a substituted vinyloxy group
with substitution selected from (C₁-C₄)alkyl, cyano, carboxy, or (C₆-C₁₀)aryl
selected from phenyl, -naphthyl or -napththyl; R⁴R⁵ amino(C₁-C₄)alkoxy group,
wherein R⁴R⁵ is a straight or branched (C₁-C₄)alkyl selected from methyl, ethyl,
n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R⁴R⁵ is
(CH₂)m, m=2-6, or (CH₂)₂ W(CH₂)₂ wherein W is selected from –N(C₁-
C₃)alkyl,O,S, –NH, –NOB and B is selected from hydrogen or (C₁-C₃)alkyl; or
R⁴R⁵ aminoxy group, wherein R⁴R⁵ is a straight or branched (C₁-C₄)alkyl selected
from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl,
2-methylpropyl, or 1,1-dimethylethyl or R⁴R⁵ is (CH₂)m, m=2-6, or –(CH₂)₂
W(CH₂)₂ wherein W is selected from –N(C₁-C₃)alkyl, O,S, –NH, –NOB and B is
selected from hydrogen or (C₁-C₃)alkyl;
and when R=R⁴ (CH₂)n CO– and n=1-4, R⁴ is selected from amino;
a substituted (C₃-C₆)cycloalkyl group with substitution selected from cyano, amino or
(C₁-C₃)acyl; a substituted(C₆-C₁₀)-aryl group with substitution selected from halo,
(C₁-C₄)-alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano,(C₁-C₄)alkoxycarbonyl,
(C₁-C₃)alkylamino or carboxy; acyloxy or haloacyloxy group selected from acetyl,
propionyl, chloroacetyl, trichlorocetyl, (C₃-C₈)cycloalkylcarbonyl, (C₆-C₁₀)aroyl
selected from benzoyl or naphthoyl, halo substituted (C₆-C₁₀)aroyl, (C₁-
C₄)alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined
hereinabove;
(C₁-C₄)alkoxy; C₆-aryloxy selected from phenoxy or substituted phenoxy with substitution
selected from halo, (C₁-C₄)-alkyl, nitro, cyano, thiol, amino, carboxy, di(C₁-
C₄)-alkylamino; (C₇ -C₁₀)aralkyloxy; (C₁-C₃)alkylthio group selected from
methythio, ethylthio, propylthio or allylthio; C₆-arylthio group selected from
phenylthio or substituted phenylthio with substitution selected from halo, (C₁-
C₄)alkyl, nitro, cyano, thiol, amino, carboxy, di(C₁₋C₈)alkylamino; C₆-arylsulfonilyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C₁₋C₄)alkoxy, trihalo(C₁₋C₃)alkyl, nitro, amino, cyano, (C₁₋ 
C₄)alkoxycarbonyl, (C₁₋C₅)alkylamino or carboxy; (C⁷ -C⁸)aralkythio group; a 
heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or 
branched chain (C₁₋C₈)- alkylamino with the alkyl selected from methyl, ethyl, 
n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 
1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 
3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 
2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; 
(C₂₋C₅)azacycloalkyl group; a carboxy(C₂₋C₄)alkylamino group with the carboxy 
alkyl selected from aminoactic acid, -aminopropanionic acid, -aminobutyric acid 
and the optical isomers thereof; -hydroxy(C₁₋C₅)alkyl selected from 
hydroxymethyl, -hydroxyethyl or -hydroxy-1-methylethyl or -hydroxypropyl; 
halo(C₁₋C₃)alkyl group; acyl or haloacyl selected from acetyl, propionyl, 
chloroacetyl, trifluoroacetyl; (C₅₋C₈)cycloalkylcarbonyl; (C₆₋C₁₀)aryloy selected 
from benzoxy or naphthoyl; halo substituted (C₆₋C₁₀)aryloy; (C₁₋C₄)alkylbenzoyl, or 
(heterocycle)carbonyl, the heterocycle as defined hereinabove; 
(C₁₋C₄)alkoxyacarbonylamino, group selected from tert-butoxycarbonylamino, 
alloyoxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or 
propoxycarbonylamino; (C₁₋C₄)alkoxyacarbonyl group selected from 
methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, 
alloyoxycarbonyl or straight or branched butoxycarbonyl; R^aR^b - amino(C₁₋ 
C₅)alkoxy group wherein R^aR^b is a straight or branched (C₁₋C₄)alkyl selected 
from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 
2-methylpropyl or R^aR^b is (CH)m m=2-6 or -(CH₂)₂ W(CH₂)₂ -wherein W is 
selected from -N(C₁₋C₅)-alkyl, O, S, -NH, -NO₂, and B is selected from 
hydrogen or C₁₋C₅)alkyl; or R^aR^b aminooxy group, wherein R^aR^b is a straight or 
branched (C₁₋C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, 
n-butyl, 1-methylpropyl, 2-methylpropyl or R^aR^b is (CH₂)m, m=2-6, or -(CH₂)₂
WO 2006/121713

PCT/US2006/016860

W(\text{CH}_2)_2 - wherein W is selected from \(-\text{N(C}_1\text{-C}_3\text{-alkyl), O,S, -NH, -NOB and B is selected from hydrogen or (C}_1\text{-C}_2\text{-alkyl, and when R=R}^d\text{ (CH}_2\text{)_n SO}_2\text{-and n=0}}

R^d\text{ is selected from amino; monosubstituted amino selected from straight or branched (C}_1\text{-C}_8\text{-alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolol, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C}_3\text{-C}_9\text{)cycloalkyl group with substitution selected from cyano, amino or (C}_1\text{-C}_3\text{)acyl; halo(C}_1\text{-C}_3\text{)alkyl group; a heterocycle as defined hereinabove;}

R^a\text{R}^b\text{ amino (C}_1\text{-C}_4\text{) alkoxy group, wherein R}^a\text{R}^b\text{ is a straight or branched (C}_1\text{-C}_4\text{-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R}^a\text{R}^b\text{ is (CH}_2\text{)_m, m=2-6, or -(CH}_2\text{)_n W-(CH}_2\text{)_2 - wherein W is selected from -N(C}_1\text{-C}_3\text{) alkyl, O, S, -NH, -NOB and B is selected from hydrogen or (C}_1\text{-C}_3\text{-alkyl; or R}^a\text{R}^b\text{ aminoxy group, wherein R}^a\text{R}^b\text{ is a straight or branched (C}_1\text{-C}_4\text{)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R}^a\text{R}^b\text{ is (CH}_2\text{)_m, m=2-6, or -(CH}_2\text{)_n W(CH}_2\text{)_2 - wherein W is selected from -N(C}_1\text{-C}_3\text{) alkyl, O, S, -NY, -NOB and B is selected from hydrogen or (C}_1\text{-C}_3\text{) alkyl; and when R=R}^d\text{ (CH}_2\text{)_n SO}_2\text{- and n=1-4,}

R^d\text{ is selected from C}_1\text{-C}_4\text{carboxyalkyl; a substituted (C}_3\text{-C}_9\text{)cycloalkyl group with substitution selected from cyano, amino or (C}_1\text{-C}_3\text{-acyl; (C}_1\text{-C}_4\text{-alkoxy; C}_6\text{-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C}_1\text{-C}_3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C}_1\text{-C}_3\text{) alkylamino; (C}_7\text{-C}_10\text{)arylalkoxy; R}^a\text{R}^b\text{ amino (C}_1\text{-C}_4\text{) alkoxy, wherein R}^a\text{R}^b\text{ is a straight or branched (C}_1\text{-C}_4\text{-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R}^a\text{R}^b\text{ is (CH}_2\text{)_m, m=2-6, or -(CH}_2\text{)_n W(CH}_2\text{)_2 - wherein W is selected from -N(C}_1\text{-C}_3\text{) alkyl, O,S, -NY, or NOB and B is selected from hydrogen or (C}_1\text{-C}_3\text{)alkyl; or R}^a\text{R}^b\text{ aminoxy group, wherein R}^a\text{R}^b\text{ is a straight or branched (C}_1\text{-C}_4\text{)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R}^a\text{R}^b\text{ is (CH}_2\text{)_m, m=2-6, or -(CH}_2\text{)_n W(CH}_2\text{)_2 - wherein W is selected from -N(C}_1\text{-C}_3\text{) alkyl, O,S, -NH, -NOB and B is
selected from hydrogen or \((C_1-C_3)\)alkyl; \((C_1-C_3)\) alkylthio selected from methylthio, ethylthio or n-propylthio; \(C_6^r\)-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, \((C_1-C_3)\)alkyl, nitro, cyano, thiol, amino, carboxy, di\((C_1-C_3)\)alkylamino; \((C_7-C_9)\) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched \((C_1-C_6)\)alkyl- amino group the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo \((C_1-C_3)\) alkyl; acyl or halocarbonyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; \((C_3-C_5)\) cycloalkylcarbonyl; \((C_6-C_{10})\) aryl selected from benzoyl or naphthoyl; halo substituted \((C_9-C_{10})\) aryl, \((C_1-C_4)\) alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; \((C_1-C_4)\)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; \(R^5\) is selected from hydrogen; straight or branched \((C_1-C_3)\) alkyl selected from methyl, ethyl n-propyl or 1-methylethyl; \((C_6-C_{10})\) aryl selected from phenyl, -naphthyl or -naphthyl; \((C_7-C_9)\) aralkyl group; a heterocycle as defined hereinabove; or \(\text{--}(CH_2)_n\text{COOR}^\gamma\) where \(n=0-4\) and \(R^\gamma\) is selected from hydrogen; straight or branched \((C_1-C_3)\)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; \((C_6-C_{10})\) aryl group selected from phenyl, -naphthyl or -naphthyl; \(R^6\) is selected from hydrogen; straight or branched \((C_1-C_3)\)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; \((C_6-C_{10})\) aryl group selected from phenyl, -naphthyl or -naphthyl; \((C_7-C_9)\)-aralkyl group; a heterocycle as defined hereinabove; or \(\text{--}(CH_2)_n\text{COOR}^\gamma\) where \(n=0-4\) and \(R^\gamma\) is selected from hydrogen; straight or branched \((C_1-C_3)\)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; \((C_6-C_{10})\)aryl selected from phenyl, -naphthyl or -naphthyl; with the proviso that \(R^5\) and \(R^6\) cannot both be hydrogen; or \(R^5\) and \(R^6\) taken together are \(\text{--}(CH_2)_q\text{W}(CH_2)_q\text{--}\), wherein \(W\) is selected from \((CH_2)_4\) and \(q=0-1\), \(-\text{NH}, -\text{N(C_1-C_3)}\)-alkyl, \(-\text{N(C_1-C_4)}\) alkoxy, oxygen, sulfur or substituted congeners
selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine;
or compounds included in U.S. Patent No. 5,494,903 which is herein incorporated by reference and at least one heparin.

In one embodiment of the disclosure, the at least one glycyclcycline is tigecycline. For example, a composition comprising at least one glycyclcycline chosen from a compound of formula I

![Chemical Structure Image]

and pharmaceutically acceptable salts thereof, and at least one heparin. For example, the heparin may be heparin sodium. In another embodiment the composition is suitable for parenteral, specifically intravenous, administration.

Another embodiment is a pharmaceutical composition comprising at least one glycyclcycline, at least one heparin and at least one pharmaceutically acceptable excipient. For example, the heparin may be heparin sodium. In another embodiment the composition is suitable for parenteral, specifically intravenous, administration.

Another embodiment is a combination therapy comprising administration of at least one glycyclcycline and at least one heparin either sequentially or as a mixture. For example, the combination therapy may produce no incompatibility as determined by at least one test chosen from color change, gas formation, visible particulate formation, turbidity and sub visible particulate formation. For example, the heparin may be heparin sodium. In another embodiment the combination therapy is suitable for parenteral, specifically intravenous, administration. By further example, the at least one glycyclcycline and the at least one heparin are administered at substantially the same time or are administered between two hours before and two hours after the at least one heparin is administered, such as for example 15 minutes, 30 minutes, 1 hour or 2 hours. For example, the heparin may be administered at the substantially the same time as tigecycline, with subsequent administration of tigecycline at, for example, 6, 12, 24 or 48
hour intervals thereafter for at least one dosing interval after initial administration. Further, for example, the heparin may be administered at substantially the same time as tigecycline, with subsequent administration of tigecycline at 12 hour intervals thereafter for 4 days after the initial administration.

Another embodiment of the disclosure is a medical apparatus comprising at least two separate compartments, wherein a first compartment comprises at least one glycolcycline and a second compartment comprises at least one heparin, and wherein the first and second compartments are connected to an administration set. For example, the first and second compartments may be connected to the same administration set and the contents of the first and second compartments may be mixed prior to administration. Optionally each compartment may be separate IV bags. By further example, the administration set may contain a Y-site where the contents of the first and second compartments are mixed prior to administration. In another embodiment, the flushing of the administration set or mixing point is not required.

Another embodiment is a method for administering at least one glycolcycline and at least one heparin, comprising administering to a patient in need thereof a therapeutically effective amount of the at least one glycolcycline, and administering to a patient in need thereof a therapeutically effective amount of at least one heparin. For example, the at least one glycolcycline and the heparin may be administered through the same site of administration. For example, this method and other methods and compositions disclosed may produce no incompatibility as determined by at least one test chosen from color change, gas formation, visible particulate formation, turbidity and sub visible particulate formation. For example, the heparin may be heparin sodium. In another embodiment the composition is suitable for parenteral, specifically intravenous, administration. By further example, the at least one glycolcycline and the at least one heparin are administered at substantially the same time or are administered between two hours before and two hours after the at least one heparin is administered, such as for example 15 minutes, 30 minutes, 1 hour or 2 hours. For example, the heparin may be administered at the substantially the same time as tigecycline, with subsequent administration of tigecycline at, for example, 6, 12, 24 or 48 hour intervals thereafter for at least one dosing interval after initial administration. Further, for example, the heparin
may be administered at substantially the same time as tigecycline, with subsequent
administration of tigecycline at 12 hour intervals thereafter for 4 days after the initial
administration.

A further embodiment is a method of administering an antibiotic comprising
administering to a patient in need thereof a therapeutically effective amount of at least
one glycyclycline, and administering to a patient in need thereof a therapeutically
effective amount of at least one heparin. For example, the glycyclycline and the heparin
are administered through the same site of administration. By further example, the at
least one glycyclycline and the at least one heparin are administered at substantially the
same time or are administered between two hours before and two hours after the at
least one heparin is administered, such as for example 15 minutes, 30 minutes, 1 hour
or 2 hours. For example, the heparin may be administered at the substantially the same
time as tigecycline, with subsequent administration of tigecycline at, for example, 6, 12,
24 or 48 hour intervals thereafter for at least one dosing interval after initial
administration. Further, for example, the heparin may be administered at substantially
the same time as tigecycline, with subsequent administration of tigecycline at 12 hour
intervals thereafter for 4 days after the initial administration.

Another embodiment is a method of treating bacterial infections, such as
complicated intra-abdominal infections (cIAI) and complicated skin and skin structure
infections (cSSSI), caused by gram-negative and gram-positive pathogens, anaerobes,
and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus
aureus (MSSA and MRSA) comprising administering to a patient in need thereof a
therapeutically effective amount of at least one glycyclycline, and administering to a
patient in need thereof a therapeutically effective amount of at least one heparin. By
further example, in the methods disclosed, the at least one glycyclycline and the at least
one heparin are administered at substantially the same time or are administered
between two hours before and two hours after the at least one heparin is administered,
such as for example 15 minutes, 30 minutes, 1 hour or 2 hours. For example, the
heparin may be administered at the substantially the same time as tigecycline, with
subsequent administration of tigecycline at, for example, 6, 12, 24 or 48 hour intervals
thereafter for at least one dosing interval after initial administration. Further, for
example, the heparin may be administered at substantially the same time as tigecycline, with subsequent administration of tigecycline at 12 hour intervals thereafter for 4 days after the initial administration.

Another embodiment is a method of administering an antibiotic to a patient receiving heparin comprising administering to a patient in need thereof a therapeutically effective amount of at least one glycylicycline. Another embodiment is a method of administering at least one glycylicycline to a patient receiving heparin comprising administering to a patient in need thereof a therapeutically effective amount of at least one glycylicycline.

Another embodiment is a method of using at least one glycylicycline in the treatment of a bacterial infection, such as those disclosed herein comprising providing a patient with a therapeutic amount of at least one glycylicycline and informing the patient and/or administering medical personnel that the at least one glycylicycline is compatible with heparin, for example the glycylicycline will not produce an incompatibility with heparin at a common point of administration.

Another embodiment is a composition comprising at least one glycylicycline, such as a pharmaceutical composition, or any composition disclosed herein comprising packaging with information that the at least one glycylicycline, such as tigecycline, may be administered with heparin. For example, the packaging may explain that there is no incompatibility at a common point of administration. Also disclosed in a method of supplying such a composition to medical personal or a patient in need thereof.

Another embodiment is a method or composition disclosed herein that further comprises a container or compartment with printed labeling advising that the at least one glycylicycline, such as tigecycline, may be administered with heparin. For example, advising that there is incompatibility at a common point of administration or that a composition disclosed herein can be administered with heparin, for example, at a common point of administration. For example, a composition or method disclosed here may further provide information that the administration of a therapeutically effective amount of at least one glycylicycline with heparin does not produce an incompatibility at a common point of administration.
One embodiment is packaging a composition comprising at least one glycyclycline with information at the at least one glycyclycline may be administered with heparin at a common point of administration without flushing the common point of administration, and methods of using such a composition.

In another embodiment, at least one glycyclycline may be provided in kits, optionally including component parts that can be assembled for use. For example, at least one glycyclycline in lyophilized form and a suitable diluent may be provided as separated components for combination prior to use. A kit may include a plurality of compartments, each compartment holding at least one unit dose of at least one glycyclycline. The compartments are preferably adapted for the desired mode of administration, including, for example, pill, tablet, capsule, powder, gel or gel capsule, sustained-release capsule, or elixir form, and/or combinations thereof, and the like for oral administration, depot products, pre-filled syringes, ampoules, vials, and the like for parenteral administration, and patches, medipads, creams, and the like for topical administration.

For example, a kit may comprise (a) at least one dosage form of at least one glycyclycline; (b) at least one compartment in which at least one glycyclycline is stored; and (c) a package insert comprising at least one of: i) information regarding the dosage amount and duration of exposure of a dosage form of at least one glycyclycline and ii) providing that the dosage form of at least one glycyclycline may be administered with heparin at a common point of administration.

In another embodiment, an article of manufacture may comprise a compartment holding at least one glycyclycline in combination with printed labeling instructions providing a discussion that indicates the compatibility of heparin and the at least one glycyclycline, for example, as opposed to other tetracyclines. The labeling instructions may be consistent, for example, with the methods of treatment as described herein before. The labeling may be associated with the compartment by any means that maintain a physical proximity of the two, by way of non-limiting example, they may both be contained in a packaging material such as a box or plastic shrink wrap or may be associated with the instructions being bonded to the compartment such as with glue that does not obscure the labeling instructions or other bonding or holding means.
For example, an article of manufacture may comprise (a) a dosage form of at least one glycyclcline, (b) a package insert or printed labeling providing that a dosage form of the at least one glycyclcline may be co-administered with heparin without flushing of a common administration site; and (c) at least one compartment in which the at least one glycyclcline is stored.

Compatibility of two or more compounds or compositions, such as tigecycline and heparin, are tested using at least one of color change, gas formation, visible particle formation, turbidity and sub-visible particle formation.

For example, color change, gas formation, visible particulate formation, and turbidity may be measured using a Black and White background light box with a fluorescent lamp capable of producing intensity of illumination between 2000 and 3750 lux.

Sub-visible particulate formation may be measured by light obscuration (HIAC) as per United States Pharmacopeia USP Chapter 788 Particulate Matter in Injections.

As a non-limiting example, an effective amount of tigecycline ranges from 0.5 mg/kg of body weight to 100.0 mg/kg of body weight, for example, from 0.5 to 15 mg/kg of body weight, by further example, from 0.5 to 1 mg/kg of body weight, may be administered from one to five times per day. For example, tigecycline may be administered as a 100 mg loading dose followed by subsequent administration of 50 mg both administered to the patient via infusion over a 30-60 minute period. In the above example, the loading dose of 100 mg may be prepared by adding two vials of reconstituted tigecycline to 100 mL Normal Saline or dextrose 5% in water ("D5W") intravenous compartments resulting in a final concentration of 1mg/mL, whereas the subsequent dose of 50 mg may be prepared by adding one vial of reconstituted tigecycline to 100 mL Normal Saline or D5W intravenous compartments resulting in a final concentration of 0.5 mg/mL. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend on a variety of factors including age, body weight, general health, sex, diet, the severity of the condition being treated, and the like.

The reconstitution of tigecycline would be understood by one skilled in the art, for example, by following instructions included by the manufacturer or distributor or by using
common medical procedures, which are inclusive of using only a sterile acceptable reconstitution medium and sterile administration compartments as described herein and in the tigecycline product label, to reconstitute and administer the lyophilized tigecycline free base supplied by the manufacturer.

Therapeutically affective amounts of heparin and formulations of heparin are well known in the art. For example, for continuous intravenous administration, an initial dose of 5,000 Units by IV injection followed by continuous dosing of 20,000 to 40,000 Units/24 hours in 1,000 mL of 0.9% Sodium Chloride Injection USP (or in any compatible solution for infusion.) As one of skill in the art would know, the dosage of heparin should be adjusted according to the patient's coagulation test results. For example, when heparin sodium is given by continuous intravenous infusion, the coagulation time should be determined approximately every four hours in the early stages of treatment. When the drug is administered intermittently by intravenous injection, coagulation tests should be performed before each injection during the early stages of treatment and at appropriate intervals thereafter. Dosage may be considered adequate when the activated partial thromboplastin time (APTT) is 1.5 to 2 times normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value. After deep subcutaneous (intrafat) injections tests for adequacy of dosage are best performed on samples drawn four to six hours after the injections.

Other than in the examples, and where otherwise indicated, all numbers used in the specification and claims are to be understood as modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however,
inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

The following example is intended to illustrate the invention in a non-limiting manner.

Example 1


To “simulate” the Y-site, solutions of both tigecycline and heparin are mixed in a 1:1 ratio, and the compatibility of the common solution is evaluated for Appearance and Description (i.e. color, visible particulates or turbidity), subvisible particulates by light obscuration (i.e. HIAC), and pH over a four hour, room temperature period. This time period has become standard when performing these “simulated Y-site” studies, although the actual residence time for the two solutions in the administration set may not exceed eight minutes prior to entering the venous system. The tigecycline test solution, before and after mixing with the counter test solution, is protected from atmospheric oxygen using a nitrogen overlay which mimics the actual “closed” system of an administration set.

The acceptance criteria of “no incompatibility indicating change” over the four hour evaluation period is being applied to the Appearance and Description assay as well as the HIAC subvisible particulate assay. Thus, for instance, formation of visible particulates or increase of subvisible particulates would indicate an incompatibility and
would result in a "Y-site incompatible" classification for that diluent or drug. In addition to the Appearance and Description and HIAC testing, the pH of the solutions are monitored "for information only." Before mixing of the two test solutions together, Appearance and Description, HIAC subvisible particulate testing, and pH are determined on each as controls.

Preparation of the Test Solutions

Preparation of Tigecycline Solution, 1 mg/ mL, in Normal Saline ("NS"). For reconstitution and admixing of the tigecycline, 0.9 % Sodium Chloride Injection, USP, 100 ml, is used.

1. Two x 5.3 mL of NS is withdrawn from a 100 mL IV solution bag.
2. Two x tigecycline 50 mg vials are each reconstituted with 5.3 ml of NS. The vials are mixed with gentle shaking, avoiding excessive or vigorous shaking of the vial.
3. Two x 5.0 ml of reconstituted tigecycline is transferred to the 100 ml NS IV solution bag used for the reconstitution. The solution is gently mixed to obtain homogeneity.
4. One hundred (100) ml of the 1 mg/ml tigecycline solution is transferred to a 250 ml beaker, flushed with nitrogen, and covered with Parafilm®

Preparation of Heparin

1. To prepare heparin in the usual dosage of 10 unit bolus in 1 ml, 10 ml are transferred from 10 vials of 10 units/ml to a clean beaker to result in 10 units/ml.
2. To prepare heparin in the usual dosage of 0.75 – 2 units/hour continuously, 10 ml of solution is removed from a 100 ml bag of 0.9 % Sodium Chloride Injection, USP. 10 ml of heparin solution is transferred from one 1,000 units/ml x 10 ml vial to the volume depleted bag of NS to result in 100 units/ml.

Testing of Controls

1. Approximately 30 ml of the tigecycline and of the heparin solution are transferred to separate beakers and evaluated for Appearance and
Description, subvisible particulates by HIAC and pH testing before the two test articles are mixed together.

2. The remaining volumes of the two test articles are used immediately.

Preparation and Testing of Combined Solutions

1. Seventy (70) ml of the heparin solution is transferred to the beaker containing the approximate 70 ml of the tigecycline solution, combined, and mixed creating the initial sample. Approximately 30 ml of the combined solution is immediately removed for 0 hour Appearance and Description, subvisible particulates by HIAC and pH testing. The beaker with the remaining solution is then recovered with Parafilm and the headspace flushed with nitrogen.

2. The sampling and testing of 30 ml aliquots is repeated after one and four hours.

Testing Performed

The following tests are performed immediately after sampling:

1. Appearance and Description for color, visible particulates, and turbidity measured using a Black and White background light box with a fluorescent lamp capable of producing intensity of illumination between 2000 and 3750 lux.

2. Sub visible particulates are measured by light obscuration (HIAC) as per United States Pharmacopeia USP Chapter 788 Particulate Matter in Injections.

pH is measured using a potentiometric meter capable of measuring pH values reproducibly within 0.02 pH units and having electrodes suitable for pH meter use.
<table>
<thead>
<tr>
<th>Assay</th>
<th>Units</th>
<th>Acceptance Criteria</th>
<th>Before mixing</th>
<th>Time after mixing, room temperature, ambient light, nitrogen flush of test sample head space</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance and Description</td>
<td>--</td>
<td>No incompatibility indicating change</td>
<td>Tigecycline Clear, yellow solution, essentially free from visible particulates</td>
<td>Clear, yellow solution, essentially free from visible particulate matter</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Heparin Clear, colorless solution, essentially free from visible particulates</td>
<td>Clear, yellow solution, essentially free from visible particulate matter</td>
</tr>
<tr>
<td>HIAC</td>
<td>≥10 μm particles/mL ≤25 μm particles/mL</td>
<td>No incompatibility indicating change</td>
<td>Tigecycline 39.3 1.4</td>
<td>29.9 0.6 22.2 0.4 12.8 0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Heparin 12.5 0.6</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>--</td>
<td>For information only</td>
<td>Tigecycline 7.78</td>
<td>7.78 7.74 7.80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Heparin 6.59</td>
<td></td>
</tr>
<tr>
<td>Assay</td>
<td>Units</td>
<td>Acceptance Criteria</td>
<td>Before mixing</td>
<td>Time after mixing, room temperature, ambient light, nitrogen flush of test sample head space</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------</td>
<td>---------------------</td>
<td>---------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Appearance and Description</td>
<td></td>
<td>No incompatibility indicating change</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tigecycline</td>
<td>0 Hours</td>
<td>0 Hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clear, yellow solution, essentially free from visible particulates</td>
<td>Clear, yellow solution, essentially free from visible particulates</td>
<td>Clear, yellow solution, essentially free from visible particulate matter</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heparin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clear, colorless solution, essentially free from visible particulates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIAC</td>
<td>≥10 μm particles/mL</td>
<td>No incompatibility indicating change</td>
<td>69.1</td>
<td>27.0</td>
</tr>
<tr>
<td></td>
<td>≥25 μm particles/mL</td>
<td></td>
<td>6.2</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tigecycline</td>
<td></td>
<td>35.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30.3</td>
<td></td>
<td>17.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heparin</td>
<td></td>
<td>1.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.7</td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td>pH</td>
<td></td>
<td>For information only</td>
<td>7.82</td>
<td>7.76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tigecycline</td>
<td></td>
<td>7.74</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7.71</td>
<td></td>
<td>7.71</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heparin</td>
<td></td>
<td>5.79</td>
</tr>
</tbody>
</table>

Table 2. Test Results for "Simulated Y-site" Compatibility Study of Tigecycline, 1 mg/mL, in NS and Heparin, 100 Units/mL, in NS
Example 2

A study is performed to determine the compatibility of tigecycline solutions with various other diluents and drugs.

All drug products are prepared per package insert directions; some drugs having wide therapeutic ranges are tested at multiple concentrations, and some drugs with different formulations are tested. A simulation of the mixing which would occur at an intravenous administration set Y-site is used, and the period for evaluation of compatibility exaggerated the generally short time that the two agents would be together prior to venous circulation. Test solutions before and after mixing are measured by visual observation, by light obscuration for subvisible particulates (HIAC), and by potentiometry over a four hour period.

The acceptance criteria of “no incompatibility indicating change” is used in assessing the data. The results are categorized into the following four classifications, as influenced by package insert statements:

1. “Compatible”, i.e. mixtures of tigecycline with diluents or other drug show no incompatibility indicating changes.
2. “Compatible with manufacture’s restrictions”, i.e. mixtures of tigecycline with drug B show no incompatibility indicating changes, but the manufacturer of drug B indicates that Y-site administration should not be performed with their drug.
3. “Incompatible”, i.e. mixtures of tigecycline with diluents or other drug show incompatibility indicating changes.
4. “Incompatible with manufacture’s restrictions”, i.e. mixtures of tigecycline with other drugs show incompatibility indicating changes, and the manufacturer of other drugs indicates that Y-site administration should not be performed with their drug.

The compatibility results are listed in Table 3 and are summarized as follows:
## Table 3

Compatibility Classifications and Concentrations of Intravenous Diluents and Drugs  
Tested under Simulated Y-site Conditions  
with Tigecycline for Injection

<table>
<thead>
<tr>
<th>Diluent</th>
<th>Usual Dose</th>
<th>Compounding Directions as Per Manufacture's Package Insert</th>
<th>Compatibility Classification</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 % Dextrose Injection</td>
<td>Continuous IV</td>
<td>Used as is</td>
<td>Compatible</td>
<td>none</td>
</tr>
<tr>
<td>5 % Dextrose and 0.9 % Sodium Chloride Injection</td>
<td>Continuous IV</td>
<td>Used as is</td>
<td>Compatible</td>
<td>none</td>
</tr>
<tr>
<td>5 % Dextrose in Lactated Ringers Injection</td>
<td>Continuous IV</td>
<td>Used as is</td>
<td>Compatible</td>
<td>none</td>
</tr>
<tr>
<td>5 % Dextrose, 0.45 % Sodium Chloride and 0.15 % Potassium Chloride Injection</td>
<td>Continuous IV</td>
<td>Used as is</td>
<td>Compatible</td>
<td>none</td>
</tr>
<tr>
<td>Lactated Ringers Injection</td>
<td>Continuous IV</td>
<td>Used as is</td>
<td>Compatible</td>
<td>none</td>
</tr>
<tr>
<td>Plasma-Lyte 56/5 % Dextrose Injection</td>
<td>Continuous IV</td>
<td>Used as is</td>
<td>Compatible</td>
<td>none</td>
</tr>
<tr>
<td>Drug</td>
<td>Usual Dose</td>
<td>Compounding Directions as Per Manufacture's Package Insert</td>
<td>Final Concentration</td>
<td>Compatibility Classification</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------</td>
<td>----------------------------------------------------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Amikacin</td>
<td>1 g over 30 minutes</td>
<td>Removed 2 ml each from 5 vials of 100 mg/2 ml Amikacin and added to the volume depleted 100 ml NS container</td>
<td>5 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>2.5 mcg/kg/minute continuously</td>
<td>Removed 1.6 ml from a 250 mg/20ml vial and diluted with 98.4 ml NS to result in 0.2 mg/ml</td>
<td>0.2 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td></td>
<td>10 mcg/kg/minute continuously</td>
<td>Removed 8.0 ml from a 250 mg/20ml vial and diluted with 92 ml NS to result in 1.0 mg/ml</td>
<td>1.0 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td>Dopamine</td>
<td>0.5-3 mcg/kg/minute continuously</td>
<td>Transferred 4 ml of 40 mg/ml to a 100 ml NS bag to result in 1.6 mg/ml</td>
<td>1.6 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>1 to 10 μg/min</td>
<td>Transferred 0.4 ml each from one 1mlx1mg/ml ampoule and ad to a 100 ml of NS to result in 4 mcg/ml</td>
<td>4 mcg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td>Gentamycin</td>
<td>350 mg over 30 minutes</td>
<td>Removed 50 ml each from 2 x 50 ml bags of 1.4 mg/ml Gentamycin and used as is</td>
<td>1.4 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>1 – 2 mg/minute continuously</td>
<td>Transferred 20 ml from each of five 20 ml vials of 2% lidocaine to a clean beaker to result in 2 % lidocaine.</td>
<td>2%</td>
<td>Compatible</td>
</tr>
<tr>
<td>Potassium (as potassium chloride)</td>
<td>20 – 40 mEq/L continuously</td>
<td>Removed 15 ml NS from a 100 ml bag. Transfer 15 ml of 2 mEq/ml Potassium chloride from one 20 ml vial to the NS bag to result in 0.3 mEq/L.</td>
<td>0.3mEq/L</td>
<td>Compatible</td>
</tr>
<tr>
<td>Drug</td>
<td>Dosage/Description</td>
<td>Calculation/Note</td>
<td>Concentration</td>
<td>Compatibility</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>6.5 mg/hour continuously</td>
<td>Transferred 2.4 ml of 25 mg/ml, 2 ml vials, from two vials to 100 ml of NS to</td>
<td>0.6 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td></td>
<td></td>
<td>result in 0.6 mg/ml.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Theophylline</td>
<td>0.4 to 4 mg/ml, not to exceed 20 mg/min</td>
<td>Used as is, as 1.6 mg/ml in D5W.</td>
<td>1.6 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>350 mg over 30 minutes</td>
<td>Removed 2 ml each from 12.5 vials of 20 mg/2 ml Tobramycin and added to the</td>
<td>2.5 mg/ml</td>
<td>Compatible</td>
</tr>
<tr>
<td></td>
<td></td>
<td>volume depleted 100 ml NS container</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Usual Dose</td>
<td>Compounding Directions as Per Manufacture's Package Insert</td>
<td>Final Concentration</td>
<td>Compatibility Classification</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>-----------------------------------------------------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Amphotericin B for Injection</td>
<td>2 mg/mL over 120 minutes</td>
<td>Two 50 mg vials are reconstituted as follows: “An initial concentrate of 5 mg per ml is first prepared by rapidly expressing 10 ml SWFI directly into the lyophilized cake, using a sterile needle (minimum diameter 20 gauge) and syringe. Shake the vial immediately until the colloidal solution is clear.” The infusion solution is then obtained by transferring the two 10 ml reconstituted volumes to the 80 ml of 5% Dextrose Injection, USP to result in 2 mg/ml.</td>
<td>2 mg/mL</td>
<td>Incompatible</td>
</tr>
</tbody>
</table>

* Test sample is not protected from light, higher concentration are used
<table>
<thead>
<tr>
<th>Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amphotericin B Lipid Complex Injection</strong></td>
</tr>
<tr>
<td>2 mg/mL over 120 minutes</td>
</tr>
<tr>
<td>Performed simulated Y-site testing despite the following PI statement: &quot;DO NOT DILUTE WITH SALINE SOLUTIONS OR MIX WITH OTHER DRUGS OR ELECTROLYTES as the compatibility of ABELCET with these materials has not been established. An existing intravenous line should be flushed with 5% Dextrose Injection before infusion of ABELCET, or a separate infusion line should be used.&quot; Diluted 20 ml of 5 mg/ml with 80 ml of D5W to result in 2 mg/ml.</td>
</tr>
<tr>
<td>2 mg/mL</td>
</tr>
<tr>
<td>Incompatible with manufacturer’s restrictions</td>
</tr>
<tr>
<td>By nature of the lipid complex of this formation resulting in high HIAC counts, sub visible particulate matter formation cannot be excluded and therefore an incompatible classification is appropriate</td>
</tr>
<tr>
<td>Drug</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>Azithromycin</td>
</tr>
<tr>
<td>Aztreonam</td>
</tr>
<tr>
<td>Cefepime</td>
</tr>
<tr>
<td>Drug</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>Cefotaxime</td>
</tr>
<tr>
<td>Ceftazidime</td>
</tr>
<tr>
<td>Drug</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Ceftriaxone</td>
</tr>
<tr>
<td>Chlorpromazine</td>
</tr>
<tr>
<td>Cimetidine</td>
</tr>
</tbody>
</table>

* Test sample is not protected from light
| Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion |
|---------------------------------------------|-----------------|---------------------------------------------|
| Ciprofloxacin                              | 1 mg/mL         | Performed simulated Y-site testing despite the following PI statement: "If the Y-type or "piggyback" method of administration is used, it is advisable to discontinue temporarily the administration of any other solutions during the infusion of Ciprofloxacin (CIPRO) IV. If the concomitant use of CIPRO IV and another drug is necessary each drug should be given separately in accordance with the recommended dosage and route of administration for each drug." Removed 10 ml from one vial of 400 mg/40 ml and dilute with 90 ml of NS to result in 1 mg/mL. | 1 mg/ml | Compatible with manufacturer's restrictions | No comments |
| Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion |
|---------------------------------|---------------------------------|-----------------|-----------------|-----------------|
| **Etrapenem**                   | 1 g/50 mL                       | Performed simulated Y-site testing despite the following PI statement: "DO NOT MIX OR CO-INFUSE INVANZ WITH OTHER MEDICATIONS." Reconstituted two 1 g vials with 10 ml of NS, shake well to dissolve, and immediately transfer to approximately 80 ml of NS to result in 20 mg/ml. | 20 mg/ml | Compatible with manufacturer's restrictions | No comments |
| **Fluconazole**                 | 400 mg (2 mg/mL) over 120 minutes | Used “as is” as a 2 mg/ml solution. | 2 mg/ml | Compatible | No comments |
| **Haloperidol**                 | 0.2 mg/mL                       | Transferred 1 ml from four 1 ml vials of 5 mg/ml to a 100 ml bag of NS to result in 0.2 mg/ml. | 0.2 mg/ml | Compatible | No comments |
| Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion |
|-----------------------------------|---------------------------------|---------------------------------|-----------------|
| Imipenem/                          | 500 mg/100mL                   | Removed 40 ml NS from a 100 ml  | 5 mg/ml          |
| cilastatin                        | over 15-30 minutes             | bag of NS. Add 10 ml of NS to each | Compatible       |
|                                  |                                | of two 250 mg vials, “shake well and |                |
|                                  |                                | transfer the resulting suspension to |                |
|                                  |                                | the infusion solution container.”  |                |
|                                  |                                | “Repeat with an additional 10 ml of  |                |
|                                  |                                | infusion solution to ensure complete  |                |
|                                  |                                | transfer of vial contents to the    |                |
|                                  |                                | infusion solution. The resulting   |                |
|                                  |                                | mixture should be agitated until    |                |
|                                  |                                | clear.” The resulting solution is 5  |                |
|                                  |                                | mg/ml.                             |                |
|                                  |                                |                                   |                |
|                                  |                                |                                   |                |
| Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Linezolid | 600 mg/300 mL over 30 – 120 minutes | Performed simulated Y-site testing despite the following PI statement: "Do not use this intravenous infusion bag in series connections. If Zyvox IV is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration." Use as is as 2 mg/ ml. | 2 mg/ml | Compatible with manufacturer’s restrictions | No comments |
| Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Methylprednisolone | 30 mg/kg/50mL over 30 minutes | Removed approximately 32 ml from a 100 ml bag of NS. "Activate" 16 "ACT-O-VIALS" by pressing down on plastic activators. Gently agitate to effect solution. Remove plastic tab., invert, and transfer 2 ml from each of the 16 vials to the volume depleted bag to result in 20 mg/ml. | 20 mg/ml | Incompatible* | By the nature of this formulation resulting in high HIAC counts, sub visible particulate matter formation cannot be excluded and therefore an incompatible classification is appropriate |
| Metoclopramide | 5 mg/mL | Removed two ml each from 50 vials of 10 mg/2ml metoclopramide and transfer to a clean 100 ml beaker for the 5 mg/ml solution. | 5 mg/ml | Compatible | No comments |

* Test sample is not protected from light.
<table>
<thead>
<tr>
<th>Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Piperacillin/tazobactam</strong></td>
</tr>
<tr>
<td><strong>Vancomycin</strong></td>
</tr>
<tr>
<td>Intravenous Drugs Potentially Administered with Tigecycline by Intermittent Infusion</td>
</tr>
<tr>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Voriconazole</td>
</tr>
</tbody>
</table>
Table 4

Example of Tigecycline - higher pH solution plus Dobutamine - lower pH solution, resulting in higher pH (after mixing) without change in Appearance and Description and Subvisible Particulates counts

<table>
<thead>
<tr>
<th>Assay</th>
<th>Units</th>
<th>Acceptance Criteria</th>
<th>Components</th>
<th>Before Mixing</th>
<th>After Mixing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tigecycline</td>
<td>Clear, yellow solution essentially free from visible particulates</td>
<td>Clear, yellow solution essentially free from visible particulates</td>
</tr>
<tr>
<td>Appearance and Description</td>
<td>-</td>
<td>No incompatibility indicating change</td>
<td>Dobutamine</td>
<td>Clear, colorless solution essentially free from visible particulates</td>
<td>Clear, yellow solution essentially free from visible particulates</td>
</tr>
<tr>
<td>Subvisible Particulates (HIAC)</td>
<td>≥10 µm particles/ml ≥25 µm particles/ml</td>
<td>No incompatibility indicating change</td>
<td>Tigecycline</td>
<td>35.8 0.9</td>
<td>22.2 0.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dobutamine</td>
<td>5.9 0.6</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>For information only</td>
<td>Tigecycline</td>
<td>7.81</td>
<td>7.52</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dobutamine</td>
<td>4.18</td>
<td></td>
</tr>
</tbody>
</table>
Table 5

Example of Tigecycline - higher pH solution plus Dopamine - lower pH solution, resulting in lower pH (after mixing) without change in Appearance and Description and Subvisible Particulates counts.

<table>
<thead>
<tr>
<th>Assay</th>
<th>Units</th>
<th>Acceptance Criteria</th>
<th>Components</th>
<th>Before Mixing</th>
<th>After Mixing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 hours</td>
<td>0 hours</td>
</tr>
<tr>
<td>Appearance and Description</td>
<td>-</td>
<td>No incompatibility indicating change</td>
<td>Tigecycline</td>
<td>Clear, yellow solution essentially free from visible particulates</td>
<td>Clear, yellow solution essentially free from visible particulates</td>
</tr>
<tr>
<td>Dopamine</td>
<td></td>
<td></td>
<td>Dopamine</td>
<td>Clear, colorless solution essentially free from visible particulates</td>
<td></td>
</tr>
<tr>
<td>Subvisible Particulates (HIAC)</td>
<td>≥10 μm particles/ml</td>
<td>No incompatibility indicating change</td>
<td>Tigecycline</td>
<td>82.3</td>
<td>37.4</td>
</tr>
<tr>
<td></td>
<td>≥25 μm particles/ml</td>
<td></td>
<td>Dopamine</td>
<td>2.2</td>
<td>0.6</td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>For information only</td>
<td>Tigecycline</td>
<td>7.84</td>
<td>4.69</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dopamine</td>
<td>3.59</td>
<td></td>
</tr>
</tbody>
</table>
Table 6

Example of Tigecycline - higher pH solution plus Chlorpromazine - lower pH solution, resulting in higher pH (after mixing) with change in Appearance and Description and Subvisible Particulates counts

<table>
<thead>
<tr>
<th>Assay</th>
<th>Units</th>
<th>Acceptance Criteria</th>
<th>Components</th>
<th>Before Mixing</th>
<th>After Mixing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 hours 0 hours</td>
<td>1 hour 4 hours</td>
</tr>
<tr>
<td>Appearance and Description</td>
<td>-</td>
<td></td>
<td>Tigecycline</td>
<td>Clear, yellow</td>
<td>Hazy, yellow</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>solution essentially free from visible particulates</td>
<td>suspension</td>
<td>suspension</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chlorpromazine</td>
<td>Clear, colorless</td>
<td>Turbid, yellow</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>solution essentially free from visible particulates</td>
<td>suspension</td>
<td>suspension</td>
</tr>
<tr>
<td>Subvisible Particulates (HIAC)</td>
<td>≥10 μm</td>
<td></td>
<td>Tigecycline</td>
<td>27.4 1.3</td>
<td>42.5 1.2</td>
</tr>
<tr>
<td></td>
<td>particles/ml</td>
<td></td>
<td></td>
<td></td>
<td>7465.3 1.3</td>
</tr>
<tr>
<td></td>
<td>≥25 μm particles/ml</td>
<td></td>
<td></td>
<td></td>
<td>17070.0 0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chlorpromazine</td>
<td>21.9 2.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No incompatibility indicating change</td>
<td>No incompatibility indicating change</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td></td>
<td>Tigecycline</td>
<td>7.74</td>
<td>7.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chlorpromazine</td>
<td>4.61</td>
<td></td>
</tr>
<tr>
<td></td>
<td>For information only</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
While the invention has been described by discussion of embodiments of the invention and non-limiting examples thereof, one of ordinary skill in the art may, upon reading the specification and claims, envision other embodiments and variations which are also within the intended scope of the invention and therefore the scope of the invention shall only be construed and defined by the scope of the appended claims.
WHAT IS CLAIMED IS:

1. A composition comprising at least one glycycline chosen from a compound of formula I

and pharmaceutically acceptable salts thereof, and at least one heparin.

2. A composition according to claim 1, wherein the glycycline is a free base.

3. A composition according to claim 1 or claim 2, wherein the heparin is heparin sodium.

4. A composition according to any one of claims 1 to 3, wherein the composition is suitable for parenteral administration.

5. A composition according to any one of claims 1 to 3, wherein the composition is suitable for intravenous administration.

6. A pharmaceutical composition as claimed in any one of claims 1 to 3, further comprising at least one pharmaceutically acceptable excipient.

7. A combination therapy comprising administration of at least one glycycline chosen from a compound of formula I
and pharmaceutically acceptable salts thereof, and at least one heparin, wherein administration is simultaneous, separate or sequential.

8. A combination therapy according to claim 7, wherein there is no incompatibility as determined by at least one test chosen from color change, gas formation, visible particulate formation, sub-visible particle formation and turbidity.

9. A combination therapy according to claim 7 or claim 8, wherein the glycylicycline is administered between two hours before and two hours after the heparin is administered.

10. A medical apparatus comprising at least two separate compartments, wherein a first compartment comprises at least one glycylicycline chosen from a compound of formula I

and pharmaceutically acceptable salts thereof and a second compartment comprising at least one heparin, and wherein the first and second compartments are connected to at least one administration set.
11. A medical apparatus according to claim 10, wherein the first and second compartments are connected to the same administration set and are mixed prior to administration.

12. A medical apparatus according to claim 11, wherein the first and second compartments are connected to the same administration set and are mixed at a Y-site prior to administration.

13. A medical apparatus according to any one of claims 10 to 12, wherein flushing of an administration set is not required.

14. A method for administering at least one glycylicycline and at least one heparin, comprising administering to a patient in need thereof a therapeutically effective amount of the at least one glycylicycline chosen from a compound of formula I and its pharmaceutically acceptable salts, and administering to a patient in need thereof a therapeutically effective amount of the at least one heparin.

15. A method for administering glycylicycline and heparin, comprising administering to a patient in need thereof a therapeutically effective amount of at least one glycylicycline chosen from a compound of formula I.
and its pharmaceutically acceptable salts, and administering to a patient in need thereof a therapeutically effective amount of at least one heparin, wherein the glycyclycline and the heparin are administered through the same site of administration.

16. A method of treating complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI), caused by gram-negative and gram-positive pathogens, anaerobes, and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA) comprising administering to a patient in need thereof a therapeutically effective amount of at least one glycyclycline chosen from a compound of formula I

and its pharmaceutically acceptable salts, and administering to a patient in need thereof a therapeutically effective amount of at least one heparin.

17. A method of treating complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI), caused by gram-negative and gram-positive pathogens, anaerobes, and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA) in a patient in need thereof, which comprises providing to said patient an effective amount of a combination
comprising a glycyclycline of formula I or a pharmaceutically acceptable salt thereof and
a heparin or a pharmaceutically acceptable salt thereof.

18. A method of administering an antibiotic comprising administering to a
patient in need thereof a therapeutically effective amount of at least one glycyclycline
chosen from a compound of formula I

![Chemical Structure](image)

(I)

and its pharmaceutically acceptable salts, and administering to a patient in need thereof
a therapeutically effective amount of at least one heparin.

19. An article of manufacture, comprising (a) a dosage form at least one
glycyclycline chosen from a compound of formula I

![Chemical Structure](image)

(I)

and its pharmaceutically acceptable salts,
(b) a package insert or printed labeling providing that a dosage form of the glycyclycline
may be co-administered with heparin without flushing of a common administration site;
and
(c) at least one compartment in which the glycyclycline is stored.

20. A kit comprising: (a) at least one dosage form of at least one glycyclycline
chosen from a compound of formula I
and its pharmaceutically acceptable salts; (b) at least one compartment in which the
glycylcycline is stored; and (c) a package insert comprising: i) information regarding the
dosage amount and duration of exposure of a dosage form of the glycylcycline and ii)
providing that the dosage form of the glycylcycline may be administered with Heparin at
a common point of administration.

21. Use of a glycylcycline of formula I or a pharmaceutically acceptable salt
thereof in the preparation of a medicament for the treatment of complicated intra-
abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI),
caused by gram-negative and gram-positive pathogens, anaerobes, and both
methicillin- susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA
and MRSA) in a patient in need thereof, which treatment also comprises administration
of a heparin of a pharmaceutical salt thereof.

22. Use of a heparin or a pharmaceutically acceptable salt thereof in the
preparation of a medicament for the treatment of complicated intra-abdominal infections
(cIAI) and complicated skin and skin structure infections (cSSSI), caused by gram-
negative and gram-positive pathogens, anaerobes, and both methicillin- susceptible and
methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA) in a patient in
need thereof, which treatment also comprises administration of a glycylcycline of formula
I or a pharmaceutical salt thereof.

23. A product comprising a glycylcycline of formula I or a pharmaceutically
acceptable salt thereof and a heparin or a pharmaceutically acceptable salt thereof as a
combined preparation for simultaneous, separate or sequential use in the treatment of
complicated intra-abdominal infections (cIAI) and complicated skin and skin structure
infections (cSSSI), caused by gram- negative and gram-positive pathogens, anaerobes,
and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA) in a patient in need thereof.